Apexian Pharmaceuticals to participate in the National Cancer Institute’s SBIR Investor Initiatives program

Indianapolis-based Apexian Pharmaceuticals, a clinical-stage biotech company developing novel compounds to treat cancer by leveraging intellectual property discovered at the Indiana University School of Medicine has been selected to participate in the National Cancer Institute’s SBIR Investor Initiatives program. As part of the program, Dr. Richard Messmann — Apexian’s chief medical officer — will present at the BioNetwork Partnering Summit taking place Oct. 23-25 in … Read more…